AN OPEN-LABEL EXTENSION STUDY TO INVESTIGATE SAFETY AND TOLERABILITY OF ML-004 IN ADOLESCENTS AND ADULTS WITH AUTISM SPECTRUM DISORDER (ASD)

Registry ID

ML-004-003

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

MAPLIGHT THERAPEUTICS, INC.

Start date

2024-04-12

Last update

2023-10-19

Conditions

• AUTISM SPECTRUM DISORDER

Related clinical trials

• PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION IN AUTISM: A PILOT TRIAL WITH PRE-POST BRAIN AND COGNITIVE MEASUREMENT TO UNDERSTAND MECHANISMS (PAT-DA)
• IMAGING ALTERATIONS IN SYNAPTIC DENSITY IN AUTISM SPECTRUM DISORDER USING A NOVEL SYNAPTIC VESICULAR PROTEIN 2A TRACER [18F]SYNVEST-1
• A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF SERTRALINE VS. PLACEBO IN THE TREATMENT OF ANXIETY IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS
• DEEP BRAIN STIMULATION FOR THE TREATMENT OF REFRACTORY REPETITIVE SELF-INJURIOUS BEHAVIOUR IN CHILDREN WITH AUTISM SPECTRUM DISORDER. A PILOT PROJECT.
• A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF ARBACLOFEN VS. PLACEBO IN THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH ASD

View on source registry